Novartis pauses autoimmune CAR-T trials on safety concerns, adding pipeline uncertainty

What happened

Novartis voluntarily paused enrollment in its autoimmune CAR-T programs following safety issues, alongside Bristol Myers Squibb, according to a note about contract manufacturer Oxford BioMedica. This adds a new negative to Novartis' pipeline, which the DeepValue report had not explicitly factored, though it already flagged a premium valuation dependent on H2 2026 catalysts. The pause does not directly affect near-term revenue drivers like Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio, but it clouds the longer-term cell therapy opportunity in autoimmune diseases. OXB shares fell 15% on the news, but Panmure Liberum called the reaction overdone, suggesting the safety issues may be manageable. For Novartis, the news likely has a modest negative impact on sentiment, but the core thesis around Pluvicto mHSPC approval and other pivotal readouts remains intact.

Implication

Investors should monitor whether the safety issues are specific to autoimmune CAR-T or signal broader problems with Novartis' cell therapy platform. Given that the master report assigned no explicit value to these programs, the direct financial impact is limited. However, the pause arrives when the stock already trades at a premium multiple with high expectations for pipeline delivery, so marginal negative news can weigh on sentiment. The key near-term catalysts remain Pluvicto mHSPC approval and the pelacarsen, remibrutinib, and del-desiran readouts; these still need to succeed to justify current valuation. We maintain our WAIT rating and suggest waiting for entry near $140 or evidence of group growth stabilization.

Thesis delta

The new safety issue adds an incremental negative to the pipeline, reducing the margin for error given the stock's premium valuation. However, the fundamental offset engine and major catalysts are unchanged, so we lower conviction slightly from 4.0 to 3.5 but keep WAIT. Confidence in the bull case is trimmed by 2 percentage points, moving to bear case, but no change to base case.